Home
University of Bergen
Øystein Fluge's picture

Øystein Fluge

Professor
Department of Clinical Science
  • E-mailOystein.Fluge@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy. Haematologica. 2454-2466.
  • Show author(s) (2023). Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study. Haematologica.
  • Show author(s) (2023). Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study. Neuro-Oncology Advances (NOA).
  • Show author(s) (2023). Gastric dysmotility and gastrointestinal symptoms in myalgic encephalomyelitis/chronic fatigue syndrome. Scandinavian Journal of Gastroenterology.
  • Show author(s) (2023). Endothelial dysfunction in ME/CFS patients. PLOS ONE. 15 pages.
  • Show author(s) (2022). Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. Haematologica. 2698-2707.
  • Show author(s) (2022). No replication of previously reported association with genetic variants in the T cell receptor alpha (TRA) locus for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Translational Psychiatry. 1-5.
  • Show author(s) (2022). Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci. Brain, Behavior, and Immunity. 362-369.
  • Show author(s) (2022). Butterfly glioblastoma: Clinical characteristics, treatment strategies and outcomes in a population-based cohort. Neuro-Oncology Advances (NOA). 1-11.
  • Show author(s) (2022). Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients. PLOS ONE. 21 pages.
  • Show author(s) (2021). Treatment approach and survival from glioblastoma: Results from a population-based retrospective cohort study from Western Norway. BMJ Open. 1-9.
  • Show author(s) (2021). Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Results From Open-Label Cyclophosphamide Intervention Study. Frontiers in medicine.
  • Show author(s) (2021). Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 1863-1877.
  • Show author(s) (2021). Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci. Brain, Behavior, and Immunity. 101-109.
  • Show author(s) (2021). A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight. 1-19.
  • Show author(s) (2020). Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress. Bone Marrow Transplantation. 1-3.
  • Show author(s) (2020). Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Advances. 1906-1915.
  • Show author(s) (2020). Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue. PLOS ONE. 1-16.
  • Show author(s) (2020). Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine. 1-15.
  • Show author(s) (2020). Human Leukocyte Antigen Alleles Associated With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Scientific Reports. 1-8.
  • Show author(s) (2019). Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation. Mitochondrion (Amsterdam. Print). 97-110.
  • Show author(s) (2019). Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma. Acta Oncologica. 1315-1322.
  • Show author(s) (2019). Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation. Bone Marrow Transplantation. 1-15.
  • Show author(s) (2019). Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics. 836-847.
  • Show author(s) (2019). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. 1-7.
  • Show author(s) (2019). Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. Acta Oncologica. 690-699.
  • Show author(s) (2019). B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 585-593.
  • Show author(s) (2018). Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. Clinical Therapeutics. 9.
  • Show author(s) (2018). Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Molecular Neurobiology. 1-9.
  • Show author(s) (2018). Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. Bone Marrow Transplantation. 1-4.
  • Show author(s) (2017). Extranodal NK/T-cell lymphoma, nasal type, primarily involving ovary. Human Pathology: Case Reports. 58-60.
  • Show author(s) (2017). Consolidative radiotherapy to residual masses after chemotherapy is associated with improved outcome in diffuse large B-cell lymphoma. A retrospective, population-based study. Clinical Lymphoma, Myeloma & Leukemia. 125-135.
  • Show author(s) (2016). Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLOS ONE.
  • Show author(s) (2016). Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation. Acta Oncologica. 547-553.
  • Show author(s) (2016). Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncologica. 81-87.
  • Show author(s) (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • Show author(s) (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • Show author(s) (2016). Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, Behavior, and Immunity. 32-39.
  • Show author(s) (2016). A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. British Journal of Haematology. 432-443.
  • Show author(s) (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 534-540.
  • Show author(s) (2015). Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica. e240-e243.
  • Show author(s) (2015). B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
  • Show author(s) (2014). Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. PLOS ONE.
  • Show author(s) (2013). Pseudoprogression in high-grade glioma. Acta Neurologica Scandinavica. 31-37.
  • Show author(s) (2013). Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987 - 2008. Tidsskrift for Den norske legeforening. 1704-1709.
  • Show author(s) (2013). High dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008. Tidsskrift for Den norske legeforening. 1704-1709.
  • Show author(s) (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology. 1385-1392.
  • Show author(s) (2012). High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. European Journal of Haematology. 395-402.
  • Show author(s) (2012). Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 1684-1691.
  • Show author(s) (2012). Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 756-762.
  • Show author(s) (2011). MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 1719-1725.
  • Show author(s) (2011). High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology. 600-610.
  • Show author(s) (2011). Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 pages.
  • Show author(s) (2010). Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology. 393-402.
  • Show author(s) (2009). Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. International Journal of Hyperthermia. 41-46.
  • Show author(s) (2009). Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica. 368-376.
  • Show author(s) (2009). Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
  • Show author(s) (2009). Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurology. 7 pages.
  • Show author(s) (2008). Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • Show author(s) (2008). Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. International Journal of Hyperthermia. 425-441.
  • Show author(s) (2008). Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 1264-1273.
  • Show author(s) (2008). Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia. 97-110.
  • Show author(s) (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • Show author(s) (1998). Hospitalization for lung disease in early childhood and asthma symptoms in young adulthood. Respiratory Medicine. 1003-1009.
  • Show author(s) (1998). Fish consumption and respiratory symptoms among young adults in a Norwegian community. European Respiratory Journal. 336-340.
Academic lecture
  • Show author(s) (2023). EFFECTS OF HIGH VS. MODERATE INTENSITY COMBINED STRENGTH AND ENDURANCE TRAINING DURING CHEMOTHERAPY ON CARDIORESPIRATORY FITNESS, MUSCLE STRENGTH AND ENDURANCE IN WOMEN WITH BREAST CANCER.
Reader opinion piece
  • Show author(s) (2018). Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon . Tidsskrift for Den norske legeforening. 12-13.
  • Show author(s) (2017). Mer om pyruvat dehydrogenase og kronisk utmattelsessyndrom. Tidsskrift for Den norske legeforening.
  • Show author(s) (2017). Chronic fatigue syndrome and pyruvate dehydrogenase function. Tidsskrift for Den norske legeforening.
Academic commentary
  • Show author(s) (2018). Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon.
Letter to the editor
  • Show author(s) (2016). Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Blood Cancer Journal.
Doctoral dissertation
  • Show author(s) (2004). Gene expression in papillary thyroid carcinomas, with special reference to tyrosine kinase receptors and growth factors.
Academic chapter/article/Conference paper
  • Show author(s) (2009). Kreftceller og kjemoterapi. 25 pages.
  • Show author(s) (2006). Thyroid Cancer: Molecular Biology and Clinical Aspects. 14 pages.
Abstract
  • Show author(s) (2012). Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 1 pages.
  • Show author(s) (2011). (18)FDG PET/CT AFTER INTENSIFIED CHEMO-IMMUNOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), AGED 18-65 YEARS WITH AAIPI 2-3. POSITIVE OR INDETERMINATE LESIONS HAVE A LOW POSITIVE PREDICTIVE VALUE. A NORDIC PHASE II SUBSTUDY. Annals of Oncology. 159-159.
  • Show author(s) (2010). R-CHOEP-14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years. Blood. 1157-1157.
  • Show author(s) (2010). High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study. Blood. 1686-1686.
  • Show author(s) (2010). Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood. 1281-1281.
  • Show author(s) (2010). Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood. 1281-1281.
Academic literature review
  • Show author(s) (2023). Understanding, diagnosing, and treating Myalgic encephalomyelitis/chronic fatigue syndrome – State of the art: Report of the 2nd international meeting at the Charité Fatigue Center. Autoimmunity Reviews.
  • Show author(s) (2021). Pathomechanisms and possible interventions in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Journal of Clinical Investigation.
  • Show author(s) (2008). Analkreft. Tidsskrift for Den norske legeforening. 198-200.
Chapter
  • Show author(s) (2016). Kreftbiologi og medikamentell terapi. 13-46. In:
    • Show author(s) (2016). Medikamentell kreftbehandling - Cytostatikaboken 8. utgave 2016. Universitetet i Oslo.

More information in national current research information system (CRIStin)